16 124 818 livres à l’intérieur 175 langues
2 047 051 livres numériques à l’intérieur 101 langues
Cela ne vous convient pas ? Aucun souci à se faire ! Vous pouvez renvoyer le produit dans les 30 jours
Impossible de faire fausse route avec un bon d’achat. Le destinataire du cadeau peut choisir ce qu'il veut parmi notre sélection.
Politique de retour sous 30 jours
Affecting approximately one percent of the adult world population, rheumatoid arthritis is the most common inflammatory joint disease. Due to its positive benefit-risk ratio, Methotrexate (MTX) is first-line therapy in rheumatoid arthritis. Although the drug is very effective, the large inter-patient variability regarding efficacy and frequency of adverse events are major drawbacks. The author describes a randomized, double-blinded controlled clinical trial, investigating the role of methotrexate polyglutamates as a marker for clinical response. Based on the detailed analysis of pharmacokinetic parameters, a pharmacokinetic-pharmacodynamic-pharmacogenomic model of MTX was established. MTXPG2, a short-chain polyglutamate, was identified as a potential marker for clinical response. The results, that MTX modulates key cytokines involved in the pathogenesis of the disease, provide important insights into its mode of pharmacological action. This book is directed toward physicians and clinical scientists who want to gain a better unterstanding of the use of MTX in rheumatoid arthritis.